-+ 0.00%
-+ 0.00%
-+ 0.00%

Goldman Sachs Maintains Neutral on Moderna, Raises Price Target to $137

Benzinga·10/15/2026 11:25:02
Goldman Sachs analyst Salveen Richter maintains Moderna (NASDAQ:MRNA) with a Neutral and raises the price target from $120 to $137.